HPLC (High Performance Liquid Chromatography) detection method for sitagliptin phosphate raw material medicine and related

By optimizing the HPLC detection method, using octadecylsilane bonded silica gel column and gradient elution technology, the problem of separation of impurities and main components in sitagliptin phosphate raw materials was solved, and effective separation and quantification of various impurities were achieved. Test to meet the quality control needs of sitagliptin phosphate finished products.

CN119086788APending Publication Date: 2024-12-06CHANGZHOU PHARMA FACTORY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411296816.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-18
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing HPLC detection methods cannot effectively separate impurities and main components in sitagliptin phosphate raw materials, making it difficult to control the content of impurities during the production process.

Method used

Using an HPLC detection method including steps, an octadecylsilane bonded silica gel column is used, the column temperature is 15-25°C, the flow rate is 0.15-0.25ml/min, the UV detector wavelength is 200-210nm, and the diluent is 0.1% phosphoric acid solution -Acetonitrile=90:10, mobile phase A is 0.01~0.025mol/L gradient elution of dipotassium hydrogen phosphate solution and methanol, achieving separation and quantitative detection of various impurities and main components.

Benefits of technology

It realizes effective separation and quantitative detection of various impurities and main components, which is simple and easy to perform, meets the needs of routine analysis and quantitative detection of sitagliptin phosphate and its related substances, and has good special attributes, detection limits, linear ranges, Accuracy, precision and durability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119086788A_ABST
    Figure CN119086788A_ABST
Patent Text Reader

Abstract

The invention provides the HPLC detection method for the sitagliptin phosphate bulk drug and the related substances thereof, effective separation and quantitative detection of various impurities can be realized, effective separation among chromatographic peaks is realized, the peak shape of each chromatographic peak is good, the conditions of sitagliptin phosphate and the related substances thereof can be accurately qualitatively and quantitatively determined, and the method is simple, convenient and easy to implement; the specificity, the detection limit, the quantitation limit, the linear range, the accuracy, the precision, the repeatability, the durability, the stability and other tests are good, and it is shown that the compound can be used for conventional analysis and quantitative detection of sitagliptin phosphate raw material medicine and related substances thereof, and the requirements of research, development and production are met.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of drug analysis, and in particular to an HPLC detection method for a sitagliptin phosphate raw material drug and related substances thereof. Background Art

[0002] Type II diabetes is a chronic metabolic disease that usually develops after the age of 35 to 40, accounting for more than 90% of diabetic patients. Patients are characterized by high blood sugar, relative lack of insulin, insulin resistance, etc. Sitagliptin phosphate is a dipeptidyl peptidase 4 (DPP-4) inhibitor that can improve blood sugar control in patients with type II diabetes by increasing the level of active incretin hormones. Sitagliptin phosphate is the first DPP-4 inhibitor approved by the U.S. FDA on October 17, 2006 for the treatment of type II diabetes.

[0003] Sitagliptin Phosphate, chemical name 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolone[4,3-a]pyrazine phosphate (1:1) monohydrate, molecular formula: C 16 H 15 F6N5O·H3PO4·H2O, molecular weight: 523.32, its chemical structure is:

[0004]

[0005] At present, the API of Sitagliptin phosphate is included in EP, USP and JP. The chromatographic column used for the related substances is a cyano column (150mm×4.6mm, 5μm), the mobile phase is 10mmol / L potassium dihydrogen phosphate solution (pH2.0)-acetonitrile (85:15), and the elution is isocratic. The method cannot achieve baseline separation between the related substance V and the main component, and the related substance V is a process impurity in the production of finished products, and it is a defluorinated impurity that is easily generated during the hydrogenation reduction process. During the pilot production process, the related substance V was detected in the samples of four batches, and its content was between 0.10% and 0.12%, which exceeded the limit of unknown impurities (0.10%), so the related substance V needs to be included in the quality standard for control. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide an HPLC detection method for sitagliptin phosphate raw material and its related substances, so as to solve the problem of separation of impurities and main components of sitagliptin phosphate raw material. The method is simple to operate and has strong versatility, and can be used for quality control and evaluation of sitagliptin phosphate raw material.

[0007] The technical solution of the present invention to solve the above technical problems is as follows:

[0008] The present invention provides an HPLC detection method for sitagliptin phosphate raw material and its related substances, comprising the following steps:

[0009] (1) Preparation of test solution;

[0010] (2) Preparation of control solution;

[0011] (3) Preparation of system suitability solutions;

[0012] (4) Blank solution: 0.1% phosphoric acid solution-acetonitrile v / v = 90:10;

[0013] (5) Determination method: Take the blank solution, system suitability solution, control solution, and test solution mentioned above and inject them into the high performance liquid chromatograph, record the chromatogram, and calculate the impurities by the self-control method with the correction factor added;

[0014] The HPLC detection method chromatographic conditions of the sitagliptin phosphate raw material and its related substances are:

[0015] Chromatographic column: octadecylsilane bonded silica gel column, column length 100-150 mm;

[0016] Column temperature: 15-25°C; flow rate: 0.15-0.25 ml / min; injection volume: 1-3 μl;

[0017] UV detector wavelength: 200~210nm;

[0018] Diluent v / v: 0.1% phosphoric acid solution-acetonitrile = 90:10;

[0019] Mobile phase A: v / v 0.01~0.025mol / L, adjust pH to 6~7 with phosphoric acid, dipotassium hydrogen phosphate solution: methanol = 95:5;

[0020] Mobile phase B: v / v methanol-acetonitrile = 70:30; mobile phase A and mobile phase B were used for gradient elution at different volume ratios;

[0021] The sitagliptin phosphate raw material and its related substances are 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine, (R)-3-amino-4-(2,4,5-trifluorophenyl)butyric acid, (3R)-3-amino-4-(2,5-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)butane-1-one, (3R)-3-amino-4-(2,4-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)butane-1-one. 1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one, (R)-3-(((R)-1-phenylethyl)amino)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one, 1-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one.

[0022] The chemical names and structures of the related substances of the sitagliptin phosphate raw material drug detected by the present invention are as follows:

[0023]

[0024] Furthermore, the step (1) specifically comprises taking an appropriate amount of the homemade sitagliptin phosphate bulk drug, dissolving it in a diluent and diluting it to prepare a 1.25 mg / ml solution as the test solution.

[0025] Furthermore, the step (2) specifically comprises accurately measuring an appropriate amount of the test solution, diluting it with a diluent to prepare a solution with a concentration of 1.25 μg / ml as a control solution.

[0026] Furthermore, the step (3) is specifically to accurately take appropriate amounts of the sitagliptin phosphate reference substance and the related substance reference substances, respectively, add appropriate amounts of acetonitrile to dissolve them, and use a diluent to prepare a solution containing 1.25 mg / ml of sitagliptin phosphate and 1.875 μg / ml of the related substances as the system suitability solution.

[0027] Furthermore, the chromatographic conditions are as follows: column temperature is 18-20°C; flow rate is 0.18-0.22 ml / min, and detection wavelength of UV detector is 203-207 nm.

[0028] Furthermore, the chromatographic column used had a size of 2.1×100 mm, 1.7 μm, and a column temperature of 20°C; the flow rate was 0.2 ml / min, the injection volume was 1 μl, and the detection wavelength of the UV detector was 205 nm; the mobile phase A was 0.01 mol / L potassium dihydrogen phosphate solution (the pH value was adjusted to 6.6 with phosphoric acid): methanol = 95:5; the mobile phase B was methanol: acetonitrile = 70:30.

[0029] If there is a conflict between the Chinese name and the structural formula of the compound in the present invention, the structural formula shall prevail, unless there is an obvious error in the structural formula.

[0030] The beneficial effects of the present invention are as follows: the present invention provides an HPLC detection method for sitagliptin phosphate raw material and its related substances, by repeatedly optimizing and screening the chromatographic conditions, including the pH of the mobile phase (1.96-10.82); the type of chromatographic column (C 18 Column, Phenyl column, Cyano column, PFP column); mobile phase (organic phase and additives); different gradients; diluent; chromatographic column temperature, etc., finally determine the analytical method of the present invention. The method can achieve effective separation and quantitative detection of multiple impurities and main components, and achieve effective separation between each chromatographic peak. The method is simple and easy. Its specificity, detection limit and quantitative limit, linear range, accuracy, precision, repeatability, durability and other tests are all good, and it can be used for routine analysis and quantitative detection of finished sitagliptin phosphate and its related substances, meeting the needs of research and development and production. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 This is the system suitability spectrum of related substances of sitagliptin phosphate raw material;

[0032] Figure 2 This is the linear relationship diagram of sitagliptin phosphate related substances Ⅰ;

[0033] Figure 3 This is the linear relationship diagram of sitagliptin phosphate related substances II;

[0034] Figure 4 This is the linear relationship diagram of sitagliptin phosphate related substances III;

[0035] Figure 5 This is the linear relationship diagram of sitagliptin phosphate related substance IV;

[0036] Figure 6 This is the linear relationship diagram of sitagliptin phosphate related substance V;

[0037] Figure 7 This is the linear relationship diagram of sitagliptin phosphate. DETAILED DESCRIPTION

[0038] The present invention is described below with reference to examples, but the present invention is not limited thereto. In the art, simple replacement or improvement made by technicians in the field to the present invention belongs to the technical solution protected by the present invention.

[0039] Embodiment 1:

[0040] (1) Experimental instrument: Angilent 1290UPLC with UV detector

[0041] Column: Waters Acquity UPLC BEH C 18 (2.1×100mm, 1.7μm)

[0042] Waters Acquity UPLC BEH Phenyl(2.1×100mm, 1.7μm)

[0043] Waters Acquity UPLC HSS Cyano (2.1×100mm, 1.8μm)

[0044] Waters Acquity UPLC HSS PFP (2.1×100mm, 1.8μm)

[0045] Detection wavelength: 205nm

[0046] Flow rate: 0.2ml / min

[0047] Column temperature: 30°C

[0048] Mobile phase: Mobile phase A: v / v 0.1% trifluoroacetic acid; Mobile phase B: v / v 25mmol / L ammonium acetate; Mobile phase C: v / v 0.2% ammonia water; Mobile phase D: acetonitrile

[0049] Table 1: Gradient elution program

[0050]

[0051]

[0052] (2) Implementation steps

[0053] Diluent v / v: 0.1% phosphoric acid-acetonitrile = 9:1

[0054] Mixed positioning solution: Weigh about 10 mg of impurity reference substance related substance I, related substance II, related substance III, related substance IV, related substance V, related substance VI, and related substance VII respectively, place them in the same 10 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and use as impurity stock solution; accurately weigh 27.17 mg of sitagliptin phosphate reference substance, place it in a 20 ml volumetric flask, accurately add 2 ml of impurity stock solution, add diluent to dissolve and dilute to the scale, and shake well.

[0055] Table 2: Separation degree of each impurity and number of impurities detected

[0056]

[0057] Both the Cyano column and the 5-fluorophenyl column (PFP) detected 7 chromatographic peaks within the corresponding use range. 18 The phenyl column and the phenyl column can detect 8 chromatographic peaks at pH 6.9 and above. Under the same pH conditions, C 18 The column separation is better than that of the phenyl column, and the separation increases with the increase of pH value. Since this product is unstable under alkaline conditions, weak acid conditions are selected as the mobile phase for this product. By continuously screening the mobile phase, column temperature and other conditions, the following are finally determined:

[0058] Column: Waters Acquity UPLC BEH C 18 (100mm×2.1mm, 1.7μm)

[0059] Mobile phase A: 0.01 mol / L potassium dihydrogen phosphate (pH adjusted to 6.6 with phosphoric acid)-methanol (95:5)

[0060] Mobile phase B: methanol-acetonitrile (7:3)

[0061] Column temperature: 20℃

[0062] Detection wavelength: 205nm

[0063] Flow rate: 0.2ml / min

[0064] Injection volume: 1 μl

[0065] Elution procedure:

[0066] T / min 0 3 15 20 25 25.1 30 A / % 90 90 45 20 20 90 90 B / % 10 10 55 80 80 10 10

[0067] Embodiment 2:

[0068] (1) Experimental instrument: Waters UPLC Acquity H-Class, equipped with UV detector;

[0069] Column: Waters Acquity UPLC BEH C 18 (100mm×2.1mm, 1.7μm)

[0070] Flow rate: 0.2ml / min

[0071] Detection wavelength: 205nm

[0072] Diluent v / v: 0.1% phosphoric acid solution-acetonitrile = 90:10

[0073] Column temperature: 20℃

[0074] Injection volume: 1 μl

[0075] Mobile phase A: v / v 0.01 mol / L potassium dihydrogen phosphate (pH adjusted to 6.6 with phosphoric acid); mobile phase B: v / v methanol:acetonitrile = 7:3; mobile phase A and mobile phase B were used in different volume ratios for gradient elution according to Table 3 below.

[0076] Table 3: Gradient elution program

[0077] Time, minutes 0 3 15 20 25 25.1 30 A% 90 90 45 20 20 90 90 B% 10 10 55 80 80 10 10

[0078] (2) Implementation steps;

[0079] Blank solution: 0.1% phosphoric acid solution-acetonitrile v / v=90:10

[0080] Preparation of test solution: Take an appropriate amount of homemade sitagliptin phosphate bulk drug, dissolve it in diluent and dilute it to make a 1.25 mg / ml solution as the test solution.

[0081] Control solution: Accurately measure an appropriate amount of the test solution and dilute it with diluent to make a solution with a concentration of 1.25 μg / ml as the control solution;

[0082] System suitability solution: Accurately take appropriate amounts of sitagliptin phosphate reference substance and related substance reference substances, add appropriate amount of acetonitrile to dissolve, and use diluent to prepare a solution containing 1.25 mg / ml sitagliptin phosphate and 1.875 μg / ml related substances as the system suitability solution.

[0083] Determination method: Take 1 μl of the blank solution, system suitability solution, control solution, and test solution respectively and inject them into the HPLC, record the chromatogram, and calculate the impurities by the self-control method with correction factor added;

[0084] System suitability: The resolution between the peaks of the finished sitagliptin phosphate and its related substances is greater than 1.5. The results are shown in Table 4 below. The system suitability meets the requirements. Figure 1This is the system suitability spectrum of related substances of sitagliptin phosphate raw material.

[0085] Table 4: System suitability of sitagliptin phosphate and its related substances

[0086]

[0087] Note: During the development of the sitagliptin phosphate method, seven impurities including related substances Ⅰ and Ⅱ were studied. Among them, related substances VI and VII were controlled in the crude sitagliptin phosphate. After the crude product was refined, they were removed from the finished product. Therefore, related substances VI and VII were not included in the quality standards of sitagliptin phosphate.

[0088] Detection limit, quantification limit and injection precision: Accurately weigh appropriate amounts of sitagliptin phosphate and related substances, dilute them step by step with diluent, take a signal-to-noise ratio of about 10:1 as the quantification limit, about 3:1 as the detection limit, inject 2 injections at the detection limit concentration, and inject 6 injections continuously at the quantification limit. The results are shown in Table 5 below. The concentration levels of the quantification limit are all less than 0.05% of the test sample concentration, and the injection precision (RSD of peak area) of this level of solution is less than 10.0%.

[0089] Table 5: Detection limit, quantification limit and injection precision of sitagliptin phosphate and its related substances

[0090]

[0091] Linear range and correction factor: 8 points were selected for sitagliptin phosphate and related substances within the level range of LOQ to 0.225%. The results are shown in Table 6 below. Sitagliptin phosphate and its impurities are linear within this concentration range, and the correlation coefficients are all greater than 0.99; the impurity correction factor is between 0.2-5, and the known impurities can be effectively controlled by the self-control method with the correction factor added. The linear relationship diagram of each component is shown in Figure 2 to Figure 7 .

[0092] Table 6: Linear range and correction factors of sitagliptin phosphate and its related substances

[0093] name Concentration (μg / ml) Correlation coefficient R Correction Factor Related substances Ⅰ 0.3212~2.3507 1.0000 2.16 Related substances Ⅱ 0.3235~2.5124 0.9997 1.55 Related substances III 0.1938~2.3498 1.0000 0.89 Related substances Ⅳ 0.1963~2.1849 0.9999 0.88 Related substancesV 0.1993~2.2318 1.0000 0.88 Sitagliptin phosphate 0.1936~2.1399 0.9984 1.00

[0094] Accuracy: The recoveries of sitagliptin phosphate related substances at 0.05%, 0.12%, 0.15% and 0.18% levels were investigated, with 3 replicates for each concentration. The recoveries of each impurity at 0.05% level were between 60% and 140%, with RSD% less than 30%, and the recoveries of each impurity at 0.12%, 0.15% and 0.18% levels were between 70% and 130%, with RSD% less than 20%, indicating that the data of this method is accurate and reliable.

[0095] Repeatability: Six test sample solutions and spiked test sample solutions were prepared in parallel, with each impurity added to the spiked test sample at a level of 0.15%. The RSDs of the impurity contents in the six background test samples and spiked test sample solutions were all less than 20%, and the recoveries of each impurity in the six spiked test samples were all between 70% and 130%, with RSDs less than 20.0%.

[0096] Durability: The system suitability solution was taken at different wavelengths (203nm and 207nm); different flow rates (0.18ml / min and 0.22ml / min); different column temperatures (18℃ and 22℃); different mobile phase A pH (6.4 and 6.8); and different initial mobile phase ratios (mobile phase A: mobile phase B are 92:8 and 88:12). The results showed that the separation between the peaks was greater than 1.5, indicating good durability.

[0097] Stability: The stability of sitagliptin phosphate and related substances was investigated by placing the system suitability solution, test solution, spiked test solution (impurity limit 0.15%) and control solution at different time periods. The results showed that the above solutions were stable at room temperature for 48 hours.

[0098] Embodiment 3:

[0099] The results of the test sample determination and influencing factors, the chromatographic conditions of this example are the same as those of Example 2, and the specific results are shown in Tables 7 and 8:

[0100] Table 7: Test results

[0101]

[0102] Table 8: Experimental results of influencing factors

[0103]

[0104] In summary, the method for determining the related substances of sitagliptin phosphate of the present invention can accurately determine and quantify the sitagliptin phosphate and its related substances. The method is easy to operate and has strong versatility, and can be used for the quality control and evaluation of sitagliptin phosphate raw materials.

[0105] The above is only a preferred embodiment of the present invention. It should be pointed out that a person skilled in the art can make several modifications and improvements without departing from the inventive concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. An HPLC detection method for sitagliptin phosphate bulk drug and its related substances, characterized in that: The steps include: (1) Preparation of test solution; (2) Preparation of control solution; (3) Preparation of system suitability solutions; (4) Blank solution: 0.1% phosphoric acid solution-acetonitrile v / v = 90:10; (5) Determination method: Take the blank solution, system suitability solution, control solution, and test solution mentioned above and inject them into the high performance liquid chromatograph, record the chromatogram, and calculate the impurities by the self-control method with the correction factor added; The HPLC detection method chromatographic conditions of the sitagliptin phosphate raw material and its related substances are: Chromatographic column: octadecylsilane bonded silica gel column, column length 100-150 mm; Column temperature: 15-25°C; flow rate: 0.15-0.25 ml / min; injection volume: 1-3 μl; UV detector wavelength: 200~210nm; Diluent v / v: 0.1% phosphoric acid solution-acetonitrile = 90:10; Mobile phase A: v / v 0.01~0.025mol / L, adjust pH to 6~7 with phosphoric acid, dipotassium hydrogen phosphate solution: methanol = 95:5; Mobile phase B: v / v methanol-acetonitrile = 70:30; mobile phase A and mobile phase B were used for gradient elution at different volume ratios; The sitagliptin phosphate raw material and its related substances are 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine, (R)-3-amino-4-(2,4,5-trifluorophenyl)butyric acid, (3R)-3-amino-4-(2,5-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)butane-1-one, (3R)-3-amino-4-(2,4-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)butane-1-one. 1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one, (R)-3-(((R)-1-phenylethyl)amino)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one, 1-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one.

2. The HPLC detection method of sitagliptin phosphate bulk drug and its related substances according to claim 1, characterized in that, The step (1) specifically comprises taking an appropriate amount of the homemade sitagliptin phosphate bulk drug, dissolving it in a diluent and diluting it to prepare a 1.25 mg / ml solution as the test solution.

3. The HPLC detection method of sitagliptin phosphate bulk drug and its related substances according to claim 1, characterized in that, The step (2) specifically comprises accurately measuring an appropriate amount of the test solution, diluting it with a diluent to prepare a solution with a concentration of 1.25 μg / ml as a control solution.

4. The HPLC detection method of sitagliptin phosphate bulk drug and its related substances according to claim 1, characterized in that, The step (3) specifically comprises taking appropriate amounts of the sitagliptin phosphate reference substance and the related substance reference substances respectively, adding appropriate amounts of acetonitrile to dissolve them, and using a diluent to prepare a solution containing 1.25 mg / ml sitagliptin phosphate and 1.875 μg / ml related substances as the system suitability solution.

5. The HPLC detection method of sitagliptin phosphate bulk drug and its related substances according to claim 1, characterized in that, The gradient elution program is: 0-3min, 90%-90% A, 10%-10% B; 3-15min, 90%-45% A, 10-55% B; 15-20min, 45%-20% A, 55%-80% B; 20-25min, 20%-20% A, 80%-80% B; 25-25.1min, 20%-90% A, 80%-10% B; 25.1-30min, 90%~90% A, 10%~10% B.

6. The HPLC detection method of sitagliptin phosphate bulk drug and its related substances according to claim 1, characterized in that, The chromatographic conditions are: column temperature of 18-20°C; flow rate of 0.18-0.22 ml / min.

7. The HPLC detection method of sitagliptin phosphate bulk drug and its related substances according to claim 1, characterized in that, The UV detector detects at a wavelength of 203-207 nm.

8. The HPLC detection method of sitagliptin phosphate bulk drug and its related substances according to claim 1, characterized in that, The size of the chromatographic column used was 2.1 × 100 mm, 1.7 μm, and the column temperature was 20 °C.

9. The HPLC detection method of sitagliptin phosphate bulk drug and its related substances according to claim 1, characterized in that, The flow rate was 0.2 ml / min, the injection volume was 1 μl, and the detection wavelength of the UV detector was 205 nm.

10. The HPLC detection method of sitagliptin phosphate bulk drug and its related substances according to claim 1, characterized in that: Mobile phase A was 0.01 mol / L potassium dihydrogen phosphate solution, pH adjusted to 6.6 with phosphoric acid: methanol = 95:5; mobile phase B was methanol: acetonitrile = 70:30.

Citation Information

Cited By

  • Analysis method for determining NTTP in sitagliptin phosphate

    CN119757620A